2253 GMT - ResMed's solid 2Q update looks likely to be viewed positively by the market, RBC analyst Craig Wong-Pan reckons. He points out in a note to clients that, while the breathing-tech provider's gross margin was a touch softer than the market had been looking for, it did not go backward compared with the prior three months. Revenue was slightly stronger than both the average analyst forecast and Wong-Pan's expectation, while net income was more than 4% ahead of the analyst average forecast. Device revenues were also ahead of expectations in both the Americas and rest-of-the-world, he adds. RBC has a last-published sector-perform rating on ResMed's U.S.-listed stock. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
January 30, 2025 17:53 ET (22:53 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。